Key takeaways
Gocovri (amantadine) and Rytary (carbidopa/levodopa) are both used to treat symptoms of Parkinson's disease (PD), but they work in different ways. Gocovri is an NMDA antagonist that helps manage dyskinesia and "off" episodes by raising dopamine levels in the brain. It's taken once a day at night. Common side effects include hallucinations, dizziness, and dry mouth. Rytary, on the other hand, is a combination of carbidopa and levodopa. It works by replacing dopamine and preventing its breakdown, and it's taken three times a day. Common side effects include nausea, headache, and dizziness. Unlike Gocovri, Rytary is not available in a generic form, which can make it more expensive. Both medications can cause sleepiness and should not be stopped suddenly due to the risk of severe withdrawal symptoms.
